← Back to Screener
Crescent Biopharma, Inc. Common Stock (CBIO)
Price$21.69
Favorite Metrics
Price vs S&P 500 (26W)104.72%
Price vs S&P 500 (4W)88.33%
Market Capitalization$575.80M
All Metrics
Book Value / Share (Quarterly)$7.37
P/TBV (Annual)1.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)413.69%
Cash Flow / Share (Quarterly)$-5.24
Price vs S&P 500 (YTD)78.95%
Net Profit Margin (TTM)-870.50%
EPS (TTM)$-15.11
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$-15.11
Revenue Growth (5Y)1.31%
EPS (Annual)$-14.97
ROI (Annual)-76.81%
Gross Margin (Annual)-0.50%
Net Profit Margin (5Y Avg)-86953.02%
Cash / Share (Quarterly)$7.74
ROA (Last FY)-64.90%
EBITD / Share (TTM)$-13.16
ROE (5Y Avg)-214.46%
Operating Margin (TTM)-843.71%
Cash Flow / Share (Annual)$-5.24
P/B Ratio2.84x
P/B Ratio (Quarterly)0.81x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)33.44x
ROA (TTM)-105.64%
EPS Incl Extra (Annual)$-14.97
Current Ratio (Annual)6.56x
Quick Ratio (Quarterly)6.44x
3-Month Avg Trading Volume0.19M
52-Week Price Return-1.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.13
P/S Ratio (Annual)53.10x
Asset Turnover (Annual)0.05x
52-Week High$29.00
Operating Margin (5Y Avg)-91877.45%
EPS Excl Extra (Annual)$-14.97
CapEx CAGR (5Y)301.37%
Tangible BV CAGR (5Y)-17.70%
26-Week Price Return111.61%
Quick Ratio (Annual)6.44x
13-Week Price Return73.52%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.56x
Enterprise Value$362.607
Revenue / Share Growth (5Y)36.20%
Asset Turnover (TTM)0.05x
Book Value / Share Growth (5Y)15.76%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1401.16%
Cash / Share (Annual)$7.74
3-Month Return Std Dev91.86%
Net Income / Employee (TTM)$-3
ROE (Last FY)-76.81%
EPS Basic Excl Extra (Annual)$-14.97
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-15.11
Receivables Turnover (Annual)0.23x
ROI (TTM)-123.85%
P/S Ratio (TTM)53.10x
Pretax Margin (5Y Avg)-86945.64%
Revenue / Share (Annual)$1.04
Tangible BV / Share (Annual)$0.31
Price vs S&P 500 (52W)-36.04%
Year-to-Date Return82.88%
5-Day Price Return11.12%
EPS Normalized (Annual)$-14.97
ROA (5Y Avg)-129.05%
Net Profit Margin (Annual)-1438.05%
Month-to-Date Return18.07%
Cash Flow / Share (TTM)$-1.37
EBITD / Share (Annual)$-14.65
Operating Margin (Annual)-1407.52%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-214.46%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-15.11
P/TBV (Quarterly)4.10x
P/B Ratio (Annual)0.81x
Pretax Margin (TTM)-833.61%
Book Value / Share (Annual)$7.37
Price vs S&P 500 (13W)71.14%
Beta1.21x
P/FCF (Annual)42.12x
Revenue / Share (TTM)$0.50
ROE (TTM)-123.85%
52-Week Low$8.72
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CBIOCrescent Biopharma, Inc. Common Stock | 53.10x | — | — | — | $21.69 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Crescent Biopharma develops novel therapeutics for solid tumors, with CR-001, a bispecific antibody targeting PD-1 and VEGF designed to improve upon existing immunotherapy options. CR-001 is modeled after ivonescimab, which demonstrated superior efficacy versus Keytruda in Phase 3 testing for non-small cell lung cancer. The company is also advancing CR-002 and CR-003, antibody-drug conjugate programs targeting validated oncology indications.